Rivaroxaban For Suspension
Janssen Pharmaceuticals
Open FDA's page for this record- Discontinued date
- 09/18/2026
- Update type
- New
- Initial posting date
- 09/18/2026
- Package NDC
- 50458-575-01
- Generic name
- Rivaroxaban For Suspension
- Contact info
- 800-526-7736
- Related info
- Business Decision
- Update date
- 09/18/2026
- Presentation
- Xarelto, For Suspension, 155 mg (NDC 50458-575-01)
- Company name
- Janssen Pharmaceuticals
- Status
- To Be Discontinued
- Therapeutic category
- Hematology
- Harmonized identifiers (openFDA)
- Application number
- NDA215859
- Brand name
- XARELTO
- Generic name
- RIVAROXABAN
- Manufacturer name
- Janssen Pharmaceuticals, Inc.
- Product NDC
- 50458-575, 50458-577, 50458-580, 50458-578, 50458-579, 50458-584
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- ORAL
- Substance name
- RIVAROXABAN
- RxCUI
- 1114198, 1114202, 1232082, 1232084, 1232086, 1232088, 1549682, 1549683, 2059015, 2059017, 2588062, 2588066
- SPL ID
- 5294926b-7812-41da-a0e8-56f492198450
- SPL set ID
- 10db92f9-2300-4a80-836b-673e1ae91610
- Package NDC
- 50458-577-60, 50458-577-18, 50458-577-14, 50458-577-01, 50458-577-10, 50458-580-01, 50458-580-10, 50458-580-30, 50458-580-07, 50458-580-90, 50458-578-01, 50458-578-10, 50458-578-30, 50458-578-90, 50458-578-14, 50458-578-07, 50458-579-01, 50458-579-10, 50458-579-30, 50458-579-90, 50458-579-99, 50458-579-07, 50458-579-89, 50458-584-51, 50458-584-52, 50458-575-01
- Nui
- N0000175635, N0000175637
- Pharm class moa
- Factor Xa Inhibitors [MoA]
- Pharm class epc
- Factor Xa Inhibitor [EPC]
- UNII
- 9NDF7JZ4M3